FindTrial
Sign In

Pembrolizumab Monotherapy

DRUG2 trials

Sponsors

Harry H Yoon, PDS Biotechnology Corp.

Conditions

AdenocarcinomaGastric CancerGastroEsophageal CancerHPV Positive Oropharyngeal Squamous Cell CarcinomaMetastatic Head and Neck CancerNeoplasms, Head and NeckRecurrent Head and Neck CancerUnresectable Head and Neck Squamous Cell Carcinoma

Phase 2

Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Active, not recruitingNCT04069273
Harry H YoonAdenocarcinoma, Gastric Cancer, GastroEsophageal Cancer
Start: 2020-12-01End: 2027-12-10Target: 58Updated: 2026-09-03

Phase 3

Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
TerminatedNCT06790966
PDS Biotechnology Corp.HPV Positive Oropharyngeal Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Neoplasms, Head and Neck +2
Start: 2025-05-30End: 2026-08-25Updated: 2026-09-02

Related Papers

VERSATILE-003: A phase 3, randomized, open-label trial of PDS0101 and pembrolizumab compared with pembrolizumab for first-line treatment of patients with HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma.
Journal of Clinical Oncology2025-05-282 citations
Enhanced efficacy of anti-VEGFR2/taxane therapy after progression on immune checkpoint inhibition (ICI) in patients (pts) with metastatic gastroesophageal adenocarcinoma (mGEA).
Journal of Clinical Oncology2020-05-206 citations
Enhanced efficacy of anti-VEGFR2/taxane therapy after progression on immune checkpoint inhibition (ICI) in patients (pts) with metastatic gastroesophageal adenocarcinoma (mGEA).
Journal of Clinical Oncology2020-02-012 citations